The National Medical Products Administration (NMPA) recently approved Sanhan Huashi Granules for marketing, a category 3.2 compound preparation of traditional Chinese medicine (TCM) originated from classic recipes. This medicine is used for epidemic diseases caused by cold-dampness stagnating in the lung pattern. The drug marketing authorization holder is Jiangsu Kanion Pharmaceutical Co., Ltd.

　　The marketing of this medicine provides another therapeutic option for the treatment of epidemic diseases.